Reportlinker Adds the Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
NEW YORK, Jan. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Gastrointestinal disorders are quite diverse affecting different parts of the alimentary tract such as the pancreas, oropharynx, liver and biliary system and the alimentary canal. Causes of these disorders vary and could include genetic anomalies, the effect of certain toxins and drugs, infections, cancer and often unknown causes. Disorders of the gastrointestinal tract (GIT) are fairly common and occur in people of all ages. These disorders take up a significant share of the disease burden in developed economies and the gravity of the problem is further accentuated by the difficulty that they pose in effective management. GIT therapy area consists of some indications that can be treated through pharmacologic interventions, though significant unmet need still exists. These unmet medical needs are more common for indications such as irritable bowel syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC). An incomplete understanding of the etiologies of these diseases limits their effective treatment, leading to misguided treatment and misdiagnosis. A significant fraction of the drugs used in the GIT therapy area are for the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The therapy area overall, however, reflects significant levels of genericization with R&D efforts drifting towards novel therapies for Crohn's disease and inflammatory bowel disease (IBD). In several instances though, the shift could be out of GIT to the faster growing therapy areas such as oncology, cardiovascular disorders and autoimmune disorders.
The gastrointestinal market was valued at $49.9bn in 2008 and US took the largest share of this market (37.8%) with sales amounting to $18.8bn. The gastrointestinal market reflects a high degree of genericization and is quite mature. The other three categories of brands ($23.7bn) captured almost as much in sales as original and licensed brands together ($26.3bn), a trend much in contrast to the high-growth therapy areas such as diabetes and oncology, where genericization is less prevalent. The growth of the GI therapeutic area has so far hinged on the performance of the PPI drug class. The interplay of brands within this drug class has shaped the market dynamics. Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents. These two drug classes are led by biologics such as Remicade and Humira, which are less prone to genericization and with the appearance of newer agents such as Cimzia, the market is expected to expand further. This report provides an overview of key events in the global gastrointestinal market that have impacted treatment trends and sales potential.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios can be obtained using this report.
Scope of this report
Epidemiological analysis of the therapy area and forecast prevalence over the period 2009-14
Forecasts and analysis of the key products in the gastrointestinal market over the period 2009-14 across major classes of treatments
Detailed analysis across major classes of gastrointestinal treatment including immunosuppressants and anti-rheumatic agents
Detailed analysis of the clinically differentiated products in the gastrointestinal market pipeline and sales forecast of key R&D pipeline products in the global gastrointestinal market
Key findings from this report
Growth in the Crohn's disease and ulcerative colitis market is likely to be driven by self-injectable products. This would lead to the transition of a significant proportion of patients on Remicade therapy to these products. The convenience of self-injection would help in driving growth in this category while facilitating earlier use of drugs. These dynamics have the potential to fuel growth while expanding the market in these categories.
AstraZeneca has constituted a new company, which will be funded by three private equity firms, with several of its gastrointestinal programs. This new biotech venture of the company, called Albireo, has taken up one early stage clinical program, besides some preclinical programs of the company. The private equity firms involved are – TVM Capital, Phase4 Ventures and Scottish Widows Investment Partnership. This new venture of AstraZeneca is a bid towards streamlining its gastrointestinal development projects in key indications such as GERD and for line extensions of its market leading product Nexium.
Many of the top ten players posted a decline in sales over 2007, a fact indicative of the high degree of genericization in the market. Over all, drugs indicated for the treatment of ulcer are expected to drag down the sales of most players. Thus, companies that have maintained a more diverse drug class portfolio are expected to gain more in the long run.
Use this report to:
Develop insights into patient potential with the report's coverage of the therapy area and top ten leading gastrointestinal players today.
Quickly understand how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the gastrointestinal marketplace.
Gain up-to-date market intelligence across the gastrointestinal category and understand the major issues affecting key pharmaceutical marketers.
Understand which drug classes have the greatest potential to drive gastrointestinal franchise growth, and how pharmaceutical companies are attempting to capitalize these market opportunities.
Compare the franchises of leading pharmaceutical companies across key therapeutic classes and understand how market share of leading companies will evolve over the next six years.
The Gastrointestinal Market Outlook to 2014
Executive summary 10
Patient potential 10
Gastrointestinal market dynamics 11
Key investigational compounds 12
Leading players of the gastrointestinal market 13
Scope and methodology 14
Scope 14
Methodology 14
Scope of IMS data 15
Chapter 1 Patient potential 18
Summary 18
Introduction 19
Gastroesophageal reflux disease (GERD) 20
Overview 20
Diagnosis, treatment and management 21
Epidemiology 22
Forecast epidemiology 22
Peptic ulcer disease (PUD) 24
Overview 24
Diagnosis, treatment and management 24
Epidemiology 25
Forecast epidemiology 27
Irritable bowel syndrome (IBS) 28
Overview 28
Diagnosis, treatment and management 28
Epidemiology 30
Forecast epidemiology 31
Ulcerative colitis (UC) 32
Overview 32
Diagnosis, treatment and management 32
Epidemiology 33
Forecast epidemiology 34
Crohn's disease (CD) 35
Overview 35
Diagnosis, treatment and management 35
Epidemiology 36
Forecast epidemiology 37
Chapter 2 Gastrointestinal market dynamics 40
Summary 40
Introduction 41
Market analysis by country 41
Licensing trends 42
Key recent events 44
AstraZeneca's GI programs part of a new biotech venture 44
Kosan Biosciences licenses a preclinical program to Pfizer 45
Xifaxan to be filed for IBS 45
Dextofisopam fails in Phase IIb 46
PPI interaction with clopidogrel could adversely affect its sales 46
Market analysis by drug class 46
The GERD treatment cascade 48
Proton pump inhibitors 49
Nexium (esomeprazole): AstraZeneca 50
Takepron (lansoprazole): Takeda 53
H2RAs 54
Gaster/Pepcid (famotidine): Astellas 56
Intestinal anti-inflammatories 56
Serotonin antagonists 59
Antispasmodics/anticholinergics 61
Inflammatory bowel disease: Crohn's disease, ulcerative colitis 62
Drug classes used for IBD 63
Leading brands used in the treatment of IBD 63
Others 66
Laxatives: A snapshot of chronic constipation 66
Therapy area sales forecast 70
Leading brands 71
Leading brands forecast 72
Chapter 3 Key investigational compounds 74
Summary 74
Introduction 75
Recent R&D updates 75
Renzapride discontinued 75
Adolor to pursue OBD drug development in spite of the Entereg setback 76
Calmactin not to be pursued further for FDA approval 76
Injectable products to drive growth in the Crohn's and UC market 77
Rezonic receives complete response letter 77
Gastrointestinal market R&D 77
A snapshot of key pipeline compounds 78
Entereg (alvimopan): Adolor/GSK 78
Overview 78
Mechanism of action 79
Clinical 79
Marketing and regulatory 80
Relistor (methylnaltrexone): Wyeth/Progenics 80
Overview 80
Mechanism of action 81
Clinical 81
Marketing and regulatory 82
Kapidex /TAK-390MR (dexlansoprazole): Takeda 82
Overview 82
Mechanism of action 82
Clinical 83
Regulatory 83
Issues/competitive landscape 84
Linaclotide: Forest/Ironwood/ Almirall 84
Overview 84
Mechanism of action 84
Clinical 85
Regulatory 85
Issues/competitive landscape 86
Cimzia (certolizumab): UCB Pharma 86
Overview 86
Clinical 86
Regulatory 87
Issues/competitive landscape 87
Key investigational compounds sales forecast 88
Chapter 4 Leading players of the
gastrointestinal market 90
Summary 90
Introduction 91
AstraZeneca 93
Overview 93
Drug class focus 94
Marketed products portfolio 94
R&D pipeline analysis 95
Strategic growth analysis 96
Drivers of growth 96
Resistors of growth 97
Takeda 98
Overview 98
Drug class focus 98
Marketed products portfolio 99
R&D pipeline analysis 101
Strategic growth analysis 102
Drivers of growth 102
Resistors of growth 102
Eisai 103
Overview 103
Drug class focus 103
Marketed products portfolio 104
R&D pipeline analysis 105
Strategic growth analysis 105
Drivers of growth 105
Resistors of growth 106
Nycomed 106
Overview 106
Drug class focus 106
Marketed products portfolio 107
R&D pipeline analysis 108
Strategic growth analysis 109
Drivers of growth 109
Resistors of growth 109
Wyeth 110
Overview 110
Drug class focus 110
Marketed products portfolio 111
R&D pipeline analysis 113
Strategic growth analysis 114
Drivers of growth 114
Resistors of growth 115
Johnson & Johnson 115
Overview 115
Drug class focus 116
Marketed products portfolio 117
R&D pipeline analysis 117
Strategic growth analysis 118
Drivers of growth 118
Resistors of growth 119
Growing generic incursion in the GI market 119
Leading players' outlook through to 2014 121
Chapter 5 Appendix 122
IMS data 122
Glossary 123
Index 125
List of Figures
Figure 2.1: Global GI market sizes, 2008 42
Figure 2.2: GI market breakdown by licensing status, 2007–08 44
Figure 2.3: Drug classes CAGR comparison, 2004–08 48
Figure 2.4: Mechanism of action of mesalazine 58
Figure 4.5: Competitive dynamics of the top 10 GI market players, 2004–08 92
Figure 4.6: Drug class focus of AstraZeneca ($m), 2008 94
Figure 4.7: Drug class focus of Takeda ($m), 2008 99
Figure 4.8: Drug class focus of Eisai ($m), 2008 103
Figure 4.9: Drug class focus of Nycomed ($m), 2008 107
Figure 4.10: Drug class focus of Wyeth ($m), 2008 111
Figure 4.11: Decline trajectory of Protonix (%), 2004–08 113
Figure 4.12: Drug class focus of J&J ($m), 2008 116
List of Tables
Table 1.1: Prevalence of major GIT indications across the seven major markets, 2008 20
Table 1.2: Estimated prevalence of GERD across seven major markets, 2008 22
Table 1.3: Forecast prevalence of GERD across seven major markets, 23
Table 1.4: Estimated prevalence of PUD across seven major markets, 2008 26
Table 1.5: Forecast prevalence of PUD across seven major markets, 27
Table 1.6: Estimated prevalence of IBS across seven major markets, 2008 30
Table 1.7: Forecast prevalence of IBS across seven major markets, 31
Table 1.8: Estimated prevalence of UC across seven major markets, 2008 33
Table 1.9: Forecast prevalence of UC across seven major markets, 34
Table 1.10: Estimated prevalence of CD across seven major markets, 2008 36
Table 1.11: Forecast prevalence of CD across seven major markets, 37
Table 2.12: Distribution of the global GI market by drug class, 2007–08 47
Table 2.13: Key brands of the PPI drug class, 2008 50
Table 2.14: Key brands of the H2RA drug class, 2008 55
Table 2.15: Key brands of the intestinal anti-inflammatories drug class, 2008 58
Table 2.16: Key brands of the serotonin antagonists drug class, 2008 60
Table 2.17: Key brands of the antispasmodics/anticholinergics drug class, 2008 62
Table 2.18: Leading brands used in IBD in the seven major markets, 2008 64
Table 2.19: Key laxative brands, 2008 69
Table 2.20: GI market sales forecast by drug classes ($m), 70
Table 2.21: Leading brands of the GI market, 2008 71
Table 2.22: Top 10 brands of the GI market, sales forecast 2008–14 72
Table 3.23: Key investigational compounds in the GI market, 2009 78
Table 3.24: An overview of Entereg 79
Table 3.25: An overview of Relistor 81
Table 3.26: An overview of TAK-390MR 82
Table 3.27: An overview of linaclotide 85
Table 3.28: An overview of Cimzia 86
Table 3.29: Key GI investigational compounds sales forecast, 2008–14 88
Table 4.30: Leading players of the GI disorders market, 2008 93
Table 4.31: Leading brands of AstraZeneca, 2008 95
Table 4.32: Key pipeline compounds of AstraZeneca 96
Table 4.33: Leading brands of Takeda, 2008 100
Table 4.34: Key pipeline compounds of Takeda 101
Table 4.35: Leading brands of Eisai, 2008 104
Table 4.36: Leading brands of Nycomed, 2008 108
Table 4.37: Leading brands of Wyeth, 2008 112
Table 4.38: Key pipeline compounds of Wyeth 114
Table 4.39: Leading brands of J&J, 2008 117
Table 4.40: Key pipeline compounds of J&J 118
Table 4.41: Leading players in the GI market, sales forecast 2008–14 121
To order this report:
Pharmaceutical Industry: The Gastrointestinal Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)-652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article